variables: 816996
Data license: CC-BY
This data as json
id | name | unit | description | createdAt | updatedAt | code | coverage | timespan | datasetId | sourceId | shortUnit | display | columnOrder | originalMetadata | grapherConfigAdmin | shortName | catalogPath | dimensions | schemaVersion | processingLevel | processingLog | titlePublic | titleVariant | attributionShort | attribution | descriptionShort | descriptionFromProducer | descriptionKey | descriptionProcessing | licenses | license | grapherConfigETL | type | sort | dataChecksum | metadataChecksum |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
816996 | New bacteriologically confirmed pulmonary tuberculosis cases tested for isoniazid and rifampicin resistance with rifampicin resistance | new cases with rifampicin resistance | 2023-12-05 11:52:00 | 2024-07-25 22:54:11 | 2017-2022 | 6308 | { "unit": "new cases with rifampicin resistance", "numDecimalPlaces": 0 } |
0 | dst_rlt_rr_new | grapher/tuberculosis/2023-11-27/drug_resistance_surveillance/drug_resistance_surveillance#dst_rlt_rr_new | 2 | major | Number of new bacteriologically confirmed pulmonary tuberculosis cases tested for isoniazid and rifampicin resistance with rifampicin resistance. Isoniazid and rifampicin are antibiotics used to treat tuberculosis. | Number of new bacteriologically confirmed pulmonary tuberculosis patients with test results for rifampicin and isoniazid and with resistance to rifampicin (regardless of result for isoniazid). | [] |
int | [] |
d303bbc17ae9976627cf637ae4271456 | fb00c2620aa6fe480b828e577717e490 |